<DOC>
	<DOCNO>NCT00524277</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell express HER2/neu . Biological therapy , GM-CSF , may stimulate immune system different way stop tumor cell grow . It yet know whether vaccine therapy effective GM-CSF treating breast cancer . PURPOSE : This randomized phase II trial study vaccine therapy see well work compare GM-CSF treat patient breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine GP2 peptide/GM-CSF vaccine reduces recurrence rate HLA-A2-positive , HER2/neu-positive , node-positive , high-risk node-negative breast cancer patient randomize receive vaccine versus immunoadjuvant , sargramostim ( GM-CSF ) , alone . - To determine AE37 peptide/GM-CSF vaccine reduces recurrence rate HLA-A2-negative , HER2/neu-positive , node-positive high-risk node-negative breast cancer patient randomize receive vaccine versus immunoadjuvant , GM-CSF , alone . - To monitor invitro invivo immunologic response vaccine correlate response clinical outcome . - To monitor unexpected toxicity vaccine . OUTLINE : This multicenter study . Patients stratify accord nodal status . Patients randomize 1 4 treatment arm . - Arm I : HLA-A2-positive patient receive GP2 peptide/GM-CSF vaccine intradermally ( ID ) every 3-4 week total 6 inoculation . - Arm II : HLA-A2-positive patient receive solely GM-CSF ID - Arm III : HLA-A2-negative patient receive AE37 peptide/GM-CSF vaccine ID every 3-4 week total 6 inoculation . - Arm IV : HLA-A2-negative patient receive solely GM-CSF ID After completion study therapy , patient follow every 3 month first 24 month every 6 month additional 36 month . Booster inoculation administer 12 , 18 , 24 , 30 month date patient ' enrollment study . One booster inoculation administer timepoint ( +/- 2 week ) inoculation ( vaccine GM-CSF ) patient receive regular inoculation series .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : 1 . Lymph nodepositive breast cancer highrisk lymph nodenegative breast cancer . The latter define one follow criterion : T2 disease Grade 3 disease Lymphovascular invasion Estrogen receptor progesterone receptornegative disease HER2/neuexpressing tumor ( immunohistochemistry [ IHC ] 3+ and/or amplify fluorescence situ hybridization [ FISH ] &gt; 2.2 , N0 ( i+ ) ) 2 . HER2/neuexpressing tumor ( IHC 13+ positive FISH &gt; 1.2 ) 3 . Completion primary standard care breast cancer therapy ( i.e. , surgery , chemotherapy , immunotherapy radiation therapy appropriate per standard care patient ' specific cancer ) 4 . Clinically cancerfree ( evidence disease ) 5 . Patients may enrol 16 month completion standard primary breast cancer therapies 6 . Good performance status ( define Exclusion Criteria ) 7 . Capable informed consent Exclusion criterion : 1 . HER2/neunegative breast cancer ( IHC 0 ) 2 . Clinical and/or radiographic evidence residual persistent breast cancer 3 . Receiving immunosuppressive therapy include chemotherapy , steroid , methotrexate 4 . In poor health ( Karnofsky &lt; 60 % , ECOG &gt; /2 ) 5 . Total bilirubin &gt; 1.8 , creatinine &gt; 2 , hemoglobin &lt; 10 , platelet &lt; 50,000 , WBC &lt; 2,000 ) 6 . Active interstitial lung disease ; asthma require need bronchodilator management ; autoimmune lung disease 7 . Pregnancy ( urine hCG ) 8 . Breast feed 9 . History autoimmune disease 10 . Involved experimental protocol ( except permission study PI ) PATIENT CHARACTERISTICS : Inclusion criterion : Female male Menopausal status specify Immunologically intact recall anergy test Negative pregnancy test Exclusion criterion : Karnofsky 060 % ECOG ≥ 2 Total bilirubin &gt; 1.8 g/dL Creatinine &gt; 2.0 g/dL Hemoglobin &lt; 10.0 g/dL Platelet count &lt; 50,000/mm³ WBC &lt; 2,000/mm³ Active pulmonary disease require medication include multiple inhaler Pregnancy Breastfeeding History autoimmune disease PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Concurrent immunosuppressive therapy include chemotherapy , steroid , methotrexate Concurrent participation another experimental treatment ( except permission study investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>